Models of Ciliary Dysfunction:Time to Expand by Shoemark, Amelia
                                                                    
University of Dundee
Models of Ciliary Dysfunction
Shoemark, Amelia
Published in:







Link to publication in Discovery Research Portal
Citation for published version (APA):
Shoemark, A. (2018). Models of Ciliary Dysfunction: Time to Expand. American Journal of Respiratory Cell and
Molecular Biology, 59(3), 285-286. https://doi.org/10.1165/rcmb.2018-0072ED
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.




Models of ciliary dysfunction: time to expand  
Amelia Shoemark 
Scottish Centre for Respiratory Research, University of Dundee, Dundee, UK 
Royal Brompton Hospital, London, UK 
Multiple motile cilia line our airways and beat in a co-ordinated pattern to transport mucus away from 
the lungs. This mucociliary escalator forms one of the first defences against foreign material entering the 
lower respiratory tract and mucociliary dysfunction leaves the respiratory tract vulnerable to infection.  
Ciliary dysfunction has been identified as a feature of several common airway diseases such as asthma, 
COPD and bronchiectasis, making improvement of ciliary function a tempting target for drug 
development (1, 2). 
Primary ciliary dyskinesia (PCD) is an inherited respiratory condition affecting approximately 1:10,000 of 
the population (3). Failure of motile cilia to clear secretions from the ears, sinuses and lower airways 
results in otitis media, rhinitis, wet cough, recurrent upper and lower respiratory tract  infections and 
bronchiectasis (3). Approximately 50% individuals with PCD have complete reversal of left-right 
symmetry of the internal organs (situs inversus), complex congenital heart disease or other laterality 
defects due to disrupted ciliary function in the embryonic node. Surprisingly, there are currently no 
licensed pharmaceutical products directed at correcting ciliary function. One of the obstacles for 
development of such therapies is the lack of laboratory models to reproducibly study therapeutic effect 
on a large scale. 
Murine models of ciliary dysfunction have been developed but often, due to lack of functioning cilia in 
the brain, these murine models develop hydrocephalus and die (4, 5). Furthermore mice with 
mucociliary clearance dysfunction do not develop lung disease which mimics that of humans. 
In-vitro air liquid interface (ALI) cultures of differentiated primary epithelial cells are useful models in the 
diagnosis of PCD (6). ALI cultures, usually grown from nasal brushings, have been shown to reproduce 
the primary ciliary phenotype in PCD whereas ciliary dyskinesia secondary to bacterial or viral infection 
normalises (7). However, use of primary ALI cultures at scale presents some difficulties. Firstly facilities 
are required for growth of human derived samples which are likely to be infected with pathogenic 
micro-organisms. The largest obstacle is that primary cells can’t typically be expanded beyond 3-5 
passages leaving limited numbers of cultures from a single donor.   Consequently a large number of 
different volunteers with ciliary dysfunction willing to have a biopsy or a system to use donor lungs post 
mortem or post transplant is required to perform experiments at scale. Several methods have been 
developed to help overcome these difficulties by extending the differentiation potential of primary cells. 
These methods include, use of a murine fibroblast feeder layer, transformation of cells with BMI-1, and 
use of ROCK inhibitors to extend proliferation potential of basal cells while maintaining the potential to 
differentiate into ciliated epithelial cells (8-10). A well described immortalised cell line which could be 
reproducibly differentiated at ALI  into columnar epithelial cells with dyskinetic cilia would overcome 
many of these difficulties and allow studies to be scaled up. In the present issue of AJRCMB an article by 
researchers in Melbourne Australia  describe a dyskinetic  ciliary phenotype identified in an existing 
immortalised cell line (BCi-NS1) (11). When cultured at ALI ciliary beat frequency in these cells is lower 
than controls at ~4Hz and increases in response to known stimulus (ATP and IL-1α) demonstrating 
potential to test modifiers of ciliary beat frequency. The authors describe a circular ciliary beat pattern 
and central pair agenesis by transmission electron microscopy and propose that this model could be 
used for screening drugs to enhance ciliary beat frequency and pattern. 
Interestingly in primary cells a circular beating of the cilia when visualised from above, is associated with 
a rare form of PCD accounting for approximately 10% patients with the condition (12). Circling cilia are 
associated with defects of the central pair projections or the proteins of the radial spoke head such as 
RSPH4a, RSPH1 and RSPH9 (13). It has been suggested that the electron microscopy phenotype results 
from a twisting of the central complex and eventual loss of the central pair as a result of the circular 
beat pattern (14). Cilia in the embryonic node which control right –left symmetry ordinarily lack a 
central pair of microtubules and beat with a circular beat pattern in health.  Resultantly individuals with 
RSPH1,4a and 9 genes do not present with situs abnormalities, as nodal cilia are unaffected. A weakness 
of the study by Kuek et al, is the lack of known mechanism for the ciliary dyskinesia in the BCi-NS1 cell 
line. The authors have gone to some lengths to try and address this weakness, such as conducting 
immunofluorescent staining for RSPH1 proteins, and karyotyping with multicolour fluorescence in situ 
hybridisation for defects in chromosomal patterning. However no clear reason for the ciliary dyskinesia 
has been established and use of the model will likely be limited by this factor. Despite this, a ciliary 
dyskinesia cell line could form a useful resource to answer questions about ciliary beat frequency and 
pattern in rare and common diseases, as well as provide a reproducible model for manipulation of ciliary 
function. These cells along with alternatives created through emerging iPSc and CRISPR technology could 
be grown at ALI or as spheroids or organoids to allow an increase in the scale at which studies on ciliary 
dyskinesia can be reproducibly performed in the future. 
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